ANAVEX LIFE SCIENCES CORP. (AVXL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | -11.94M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -17.37M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-11.94M | $-17.37M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $26.10M | (m) | $9.47M | $-38.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $31.80M | (m) | $10.60M | $-44.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $37.59M | (m) | $11.55M | $-51.41M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $41.91M | (m) | $9.84M | $-54.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $43.76M | (m) | $8.00M | $-54.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $43.60M | (m) | $9.21M | $-55.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $41.84M | (m) | $9.44M | $-52.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $40.34M | (m) | $10.61M | $-51.19M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $38.76M | (m) | $11.99M | $-49.99M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $40.33M | (m) | $13.31M | $-51.66M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $43.72M | (m) | $16.37M | $-55.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $45.04M | (m) | $19.23M | $-58.39M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $44.03M | (m) | $19.35M | $-57.32M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $41.33M | (m) | $19.82M | $-54.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $37.92M | (m) | $18.38M | $-50.99M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $35.91M | (m) | $15.49M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $35.60M | (m) | $13.79M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $33.71M | (m) | $11.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $32.98M | (m) | $8.23M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $29.72M | (m) | $5.74M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $27.48M | (m) | $4.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $26.81M | (m) | $4.55M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $25.23M | (m) | $4.88M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $23.84M | (m) | $5.45M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $22.87M | (m) | $5.44M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $22.90M | (m) | $5.63M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $22.26M | (m) | $6.43M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $21.96M | (m) | $6.69M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $19.20M | (m) | $7.13M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $16.36M | (m) | $6.46M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $13.34M | (m) | $5.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $12.77M | (m) | $5.14M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $12.08M | (m) | $4.63M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $11.32M | (m) | $4.37M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $10.67M | (m) | $4.14M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $10.20M | (m) | $6.80M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $9.06M | (m) | $5.87M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $8.13M | (m) | $5.13M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $7.25M | (m) | $5.06M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $3.66M | (m) | $2.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $3.54M | (m) | $2.65M | (m) | $-7.16K | (m) | (m) | (m) | Reported |
| 2015-12-31 | $2.62M | (m) | $2.44M | (m) | $-7.33K | (m) | (m) | (m) | Reported |
| 2015-09-30 | $2.27M | (m) | $1.63M | (m) | $71.83K | (m) | (m) | (m) | Reported |
| 2015-06-30 | $1.87M | (m) | $893.79K | $-3.78M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $1.33M | (m) | $669.47K | $-3.27M | $73.50K | (m) | (m) | -44.45× | Reported |
| 2014-12-31 | $1.05M | (m) | $653.29K | $-3.43M | $80.81K | (m) | (m) | -42.45× | Reported |
| 2014-09-30 | $732.39K | (m) | $637.92K | $-2.97M | $7.09K | (m) | (m) | -418.81× | Reported |
| 2014-06-30 | $485.61K | (m) | $1.01M | $-3.80M | $26.56K | (m) | (m) | -142.99× | Reported |
| 2014-03-31 | $259.62K | (m) | $1.00M | $-2.93M | $32.92K | (m) | (m) | -88.85× | Reported |
| 2013-12-31 | $142.02K | (m) | $1.00M | $-2.03M | $44.40K | (m) | (m) | -45.74× | Reported |
| 2013-09-30 | $263.85K | (m) | $1.00M | $-2.14M | $51.34K | (m) | (m) | -41.63× | Reported |
| 2013-06-30 | $279.54K | (m) | $0.00 | $-1.31M | $49.51K | (m) | (m) | -26.49× | Reported |
| 2013-03-31 | $634.48K | (m) | $98.80K | $-1.88M | $72.64K | (m) | (m) | -25.93× | Reported |
| 2012-12-31 | $1.06M | (m) | $178.94K | $-2.55M | $106.15K | (m) | (m) | -24.01× | Reported |
| 2012-09-30 | $2.65M | (m) | $302.21K | $-4.32M | $138.34K | (m) | (m) | -31.24× | Reported |
| 2012-06-30 | $3.13M | (m) | $559.96K | $-4.91M | $204.82K | (m) | (m) | -23.95× | Reported |
| 2012-03-31 | $3.52M | (m) | $620.34K | $-5.84M | $170.83K | (m) | (m) | -34.21× | Reported |
| 2011-12-31 | $3.82M | (m) | $1.21M | $-7.00M | $124.71K | (m) | (m) | -56.13× | Reported |
| 2011-09-30 | $2.60M | (m) | $1.27M | $-6.18M | $90.25K | (m) | (m) | -68.49× | Reported |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $2.73M | (m) | $770.05K | $-5.65M | $284.96K | (m) | (m) | -19.82× | Reported |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |